Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition

Cardiac fibrosis is a common feature in chronic hypertension patients with advanced heart failure, and endothelial-tomesenchymal transition (EndMT) is known to promote Angiotensin II (Ang II)-mediated cardiac fibrosis. Previous studies have suggested a potential role for the transcription factor, ET...

Full description

Saved in:
Bibliographic Details
Published inBMB reports Vol. 52; no. 10; pp. 595 - 600
Main Authors Xu, Lian, Fu, Mengxia, Chen, Dongrui, Han, Weiqing, Ostrowski, Michael C, Grossfeld, Paul, Gao, Pingjin, Ye, Maoqing
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Society for Biochemistry and Molecular Biology 01.10.2019
생화학분자생물학회
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cardiac fibrosis is a common feature in chronic hypertension patients with advanced heart failure, and endothelial-tomesenchymal transition (EndMT) is known to promote Angiotensin II (Ang II)-mediated cardiac fibrosis. Previous studies have suggested a potential role for the transcription factor, ETS-1, in Ang II-mediated cardiac remodeling, however the mechanism are not well defined. In this study, we found that mice with endothelial Ets-1 deletion showed reduced cardiac fibrosis and hypertrophy following Ang II infusion. The reduced cardiac fibrosis was accompanied by decreased expression of fibrotic matrix genes, reduced EndMT with decreased Snail, Slug, Twist, and ZEB1 expression, as well as reduced cardiac hypertrophy and expression of hypertrophyassociated genes was observed. In vitro studies using cultured H5V cells further confirmed that ETS-1 knockdown inhibited TGF-β1-induced EndMT. This study revealed that deletion of endothelial Ets-1 attenuated Ang II-induced cardiac fibrosis via inhibition of EndMT, indicating an important ETS-1 function in mediating EndMT. Inhibition of ETS-1 could be a potential therapeutic strategy for treatment of heart failure secondary to chronic hypertension. [BMB Reports 2019; 52(10): 595-600].
Bibliography:These authors contributed equally to this work.
ISSN:1976-6696
1976-670X
DOI:10.5483/bmbrep.2019.52.10.206